水林佳治疗糖尿病性脂肪肝的疗效观察  

Clinical effect of compound silibin-phosphatidylchollne in patients with diabetic fatty liver disease

作　　者：张淑敏[1] 魏思忱[2] 孙秀芝[2] 段克东[2] 

机构地区：[1]沧州市中西医结合医院,061001 [2]沧州市中心医院消化内科

出　　处：《中国实用医药》2009年第23期23-25,共3页China Practical Medicine

摘　　要：目的探讨水林佳治疗糖尿病性脂肪肝的疗效。方法选择糖尿病性脂肪肝患者86例,随机分为试验组45例,服用水林佳70mg,3次/d;对照组41例,口服肝泰乐0.1g,3次/d,观察期为3个月。治疗前后检测肝转氮酶、血胆固醇、甘油三酯、血糖、肝纤维化三项及超声影像变化。同时观察两组患者用药期间的不良反应。结果治疗结束时,试验组ALT、AST、TC、TG及HA、LN、PC-Ⅲ均明显下降,肝脏影像学也有明显改善。对照组虽ALT、AST有所下降,但HA、LN、PC-Ⅲ和肝脏影像学无明显改善。观察期间两组均未出现明显不良反应。结论水林佳具有保肝、降血脂、改善肝纤维化的作用,对糖尿病性脂肪肝有治疗作用。Objective To assess the clinical efficacy of compound silibin-phosphatidylcholine in patients with diabetic fatty liver disease. Methods 86 patients with diabetic fatty liver disease （ abnormal ALT/ AST level）were randomly divided intotrial group treated with compound silibin- phosphatidy- lcholine and control group treated with Glucurolactone respectively for consecutive 3 months. Before and 12 weeks after treatment, the changes of serum transaminase level （ ALT/AST ）, cholesterol （ TC ）, triglyceride （ TG ）, hepatic fibrosis indicators and ultrasonic image were detected respectively. Side effect Was also observed during the experiment. Results The levels of serum ALT/AST were all obviously reduced at the end point compared with the baseline in both groups. TC. TG and hepatic fibmsis indicators were significantly reduced in trial group, but Was not in control group. The improvement rate of ultrasonic image in trial group Was more higher than that in control group and no severe side effect occurred during the experiment in both groups. Conclusion Compound silibinphosphatidylcholine has significant therapeutic effect on diabetic fatty liver disease, which shows significant effect in improving the serum parameters of liver function, lipid, hepatic fibrosis indicators and ultrasonic image.

关 键 词：水林佳 脂肪肝 糖尿病 治疗 

分 类 号：R575.5[医药卫生—消化系统] R587.1[医药卫生—内科学]